Quote from: Meta Cognition on May 27, 2015, 12:54:06 PM

Quote from: Decimator Omega on May 27, 2015, 12:52:17 PM

I eat douchebags like that for breakfast

*eats Meta Cognition*

*spits him back out*

Okay, that was the worst douchebag I've ever tasted.

I eat douchebags like that for breakfast

Why?

Scientists have the first proof that a “brand new” way of combating cancer, using genetically modified viruses to attack tumour cells, can benefit patients, paving the way for a “wave” of new potential treatments over the next decade.

Specialists at the NHS Royal Marsden Hospital and the Institute of Cancer Research (ICR) confirmed that melanoma skin cancer patients treated with a modified herpes virus (the virus that causes cold sores) had improved survival – a world first.

In some patients, the improvements were striking. Although all had aggressive, inoperable malignant melanoma, those treated with the virus therapy – known as T-VEC – at an earlier stage survived on average 20 months longer than patients given an alternative.

In other patients results were more modest, but the study represents a landmark: it is the first, large, randomised trial of a so-called oncolytic virus to show success.

Cancer scientists predict it will be the first of many in the coming years – adding a new weapon to our arsenal of cancer treatments.

The method – known as viral immunotherapy – works by launching a “two-pronged attack” on cancer cells. The virus is genetically modified so that it can’t replicate in healthy cells – meaning it homes in on cancer cells.

It multiplies inside the cancer cells, bursting them from within. At the same time, other genetic modifications to the virus mean it stimulates the body’s own immune response to attack and destroy tumours.

Other forms of immunotherapy – the stimulation of the body’s own immune system to fight cancer – using antibodies rather viruses, have been developed into successful drugs. It is hoped that T-VEC could be used in combination with these.

Findings from trials of T-VEC, which is manufactured by the American pharmaceutical company Amgen, have already been submitted to drugs regulators in Europe and the USA.

Viral immunotherapies are also being investigated for use against advanced head and neck cancers, bladder cancers and liver cancers.

Kevin Harrington, UK trial leader and professor of biological cancer therapies at the ICR and an honorary consultant at the Royal Marsden, said he hoped the treatment could be available for routine use within a year in many countries, although it would need to pass the UK’s own regulatory approval before it could be prescribed here.

“I hope, having worked for two decades in this field, that it really is the start of something really exciting,” said Professor Harrington. “We hope this is the first of a wave of indications for these sorts of [cancer fighting] agents that we will see coming through in the next decade or so.”

Professor Paul Workman, chief executive of the ICR said: “We may normally think of viruses as the enemies of mankind, but it’s their very ability to specifically infect and kill human cells that can make them such promising cancer treatments.”

The study, which is published in the Journal of Clinical Oncology, included 436 patients, all of whom had aggressive, inoperable malignant melanoma. More than 16 per cent of patients were responding to treatment after six months, compared to 2.1 per cent who were given a control treatment.

Some patients were still responding to treatment after three years.Alan Melcher, professor of clinical oncology and biotherapy at the University of Leeds, and an expert in oncolytic viruses, said the field had accelerated quickly in recent years.

“They were first developed to go in and kill cancer cells but leave other cells unharmed. What’s become clear is that these viruses may do that but what is probably more important, is that they work by stimulating an immune response against cancer,” he said.

“The field has moved very quickly clinically. Immunotherapy looks promising and big pharmaceutical companies are now involved. Amgem have bought this virus and the reality is, when the big companies get involved things move a lot more quickly.”

Dr Hayley Frend, science information manager at Cancer Research UK, said the potential for viruses in future cancer treatments was “exciting”.

“Previous studies have shown T-VEC could benefit some people with advanced skin cancer but this is the first study to prove an increase in survival. The next step will be to understand why only some patients respond to T-VEC, in order to help better identify which patients might benefit from it,” she said.

Melanoma is the fifth most common cancer in the UK, and is becoming more widespread as a result of increased exposure to the sun in younger generations who have benefitted from easier access to sunnier climates on holiday. Survival chances are good if the cancer – indicated by the appearance of a new mole on the skin – is caught early.

However, if left alone, the tumour can become inoperable, and 2,000 people still die from melanoma in the UK every year.

String theory is garbage

Quote from: FatherlyNick on May 26, 2015, 02:46:41 PM

While everyone is scared of nukes - only US has used that weapon on civilians. Twice.

I've made multiple posts on this forum proving that the two cities were legitimate military targets. Feel free to find one.

Quote from: Meta Cognition on May 26, 2015, 02:30:54 PM

- Obama is probably a borderline psychopath.

What the fuck

WE HAVE A FUCKING CLASSIC GOING RIGHT NOW.

This law is fucked up.

Persistently increasing wage inequality, polarization of the wage distribution, and stagnating real wages for low skill workers are some of the most salient features of modern labor markets, but are difficult to reconcile with the theoretical literature on economic growth. To better understand the mechanisms driving these phenomena, we construct an endogenous growth model of directed technical change with automation (the introduction of machines which replace low-skill labor and complement high-skill labor) and horizontal innovation (the introduction of new products, which increases demand for both types of labor). The economy endogenously follows three phases: First, both low-skill wages and automation are low, while income inequality and the labor share are constant. Second, increases in low-skill wages stimulate investment in automation, which depresses the growth rate of future low-skill wages (potentially to negative), and reduces the total labor share. Finally, the share of automated products stabilizes and low-skill wages grow at a positive but lower rate than high-skill wages. Adding middle skill workers allows the model to generate a phase of wage polarization after one of uniform increase in income inequality. We show that this framework can quantitatively account for the evolution of the skill premium, the skill ratio and the labor share in the US since the 1960s

Quote from: Meta Cognition on May 26, 2015, 03:13:10 PM

I didn't say it was, but the claim that "black people run faster" is not a claim of causation in the first place.

you don't really believe that most people think in those terms, though, do you?

i would argue most people are making the causative claim